title: FVIII inhibitors: pathogenesis and avoidance.
abstract: The pathogenesis of inhibitory antibodies has been the focus of major scientific interest over the last decades, and several studies on underlying immune mechanisms and risk factors for formation of these antibodies have been performed with the aim of improving the ability to both predict and prevent their appearance. It seems clear that the decisive factors for the immune response to the deficient factor are multiple and involve components of both a constitutional and therapy-related nature. A scientific concern and obstacle for research in the area of hemophilia is the relatively small cohorts available for studies and the resulting risk of confounded and biased results. Careful interpretation of data is recommended to avoid treatment decisions based on a weak scientific platform. This review will summarize current concepts of the underlying immunological mechanisms and risk factors for development of inhibitory antibodies in patients with hemophilia A and discuss how these findings may be interpreted and influence our clinical management of patients.
authors.affiliation: Department for Hematology and Vascular Medicine, Center for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden.
authors.forename: Jan
authors.initials: J
authors.lastname: Astermark
mesh_terms: D019774:Blood Coagulation Factor Inhibitors / Q000378:metabolism*; D005006:Ethnicity / Q000235:genetics; D005169:Factor VIII / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy* / Q000208:ethnology / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000235:genetics; D006801:Humans; D007518:Isoantibodies / Q000009:adverse effects / Q000378:metabolism; D044469:Racial Groups / Q000235:genetics; D012307:Risk Factors
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D000949:Histocompatibility Antigens Class II; D007518:Isoantibodies; D005169:Factor VIII